- ongoing, recruitingPhase I and Phase II (Integrated)- Other
An Open-label, Randomized Phase Ib/II Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or Refractory Multiple Myeloma
This study is for people in the UK with multiple myeloma that has come back or not responded to previous treatments. It investigates new combinations of medications, including one called Forimtamig, to see how safe and effective they are.
Spain · Denmark · France - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
Dose-Escalation Study of Cevostamab in Participants with Relapsed or Refractory Multiple Myeloma
This study is testing a new medicine called Cevostamab for adults with multiple myeloma that has come back or not responded to other treatments. It's the very first time this medicine is being given to people, to find the right dose and see if it's safe.
Spain - not yet recruitingPHASE3
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
This study, called iFIT, helps doctors find the best treatments for older myeloma patients. It checks how well standard NHS treatment works and looks at your fitness level. Then, it uses this information to decide the next steps, aiming to improve your care.
United Kingdom - recruiting
Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
This study looks at people with certain blood cancers (CLL, Multiple Myeloma) who get infections easily. Researchers want to create a simple way for patients to report infection symptoms daily using an app and see how quality of life changes over time. It aims to improve how infections are found and treated.
Austria · Germany